Oxford Immunotec releases T-SPOT Discovery SARS-CoV-2 kit for research into measuring T cell immune response to SARS-CoV-2

Oxford Immunotec releases T-SPOT Discovery SARS-CoV-2 kit for research into measuring T cell immune response to SARS-CoV-2

Oxford Immunotec Global has released the T-SPOT Discovery SARS-CoV-2 test kit. The kit is for research use only and could make a significant contribution towards development of a new tool to manage the...

Supplied by Immunotech Inc


Oxford Immunotec Global has released the T-SPOT Discovery SARS-CoV-2 test kit. The kit is for research use only and could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic.

T-SPOT Discovery SARS-CoV-2 builds on Oxford Immunotec’s experience with TB diagnosis and the assessment of immune response to CMV in transplant patients, to apply the Company’s established, proprietary T-SPOT technology to the fight against COVID-19.

While serology is able to detect antibodies to SARS-CoV-2 in the blood of some individuals after infection, little is known about how this confers immunity to COVID-19. T-SPOT technology goes further than simple serology by interrogating the immune system’s T cell response and will enable research into the measurement of the strength of that response to SARS-CoV-2. The strength of this response may be linked to protection from reinfection.

Commenting on the technology, Phill Keefe, Senior Vice President Product Design, Development and Delivery at Oxford Immunotec, said: “Not everyone with COVID-19 infection has detectable antibodies in serology tests, and this may be a bigger problem in the majority who experience only mild or no symptoms. Also, it is not yet clear whether the presence of anti-bodies confers immunity. T cell responses develop before antibody generation and can independently provide protection, so studying T cells could give us new insights into immunity to COVID-19.”

T-SPOT technology is approved in over 60 countries for clinical use to detect TB infection. With over 20 million clinical tests since release, T-SPOT technology:

  • Uses a standardized sample prepared from peripheral blood which:
    - Reduces the influence of factors which might affect results, such as other treatments
    - Standardises cell numbers in the test to normalise for cell number variations between samples
  • Allows the number of responding T cells to be enumerated for a more precise assessment of the T cell response
  • Is able to maintain performance, even in samples from immunosuppressed individuals
  • Can be run in high-volume labs enabling large testing programs to be rolled out.

T-SPOT technology can also be automated using the T-Cell Select reagent kit. Automation solutions are available for low, medium and high throughput settings.

For more information, visit: go.oxfordimmunotec. com/t-spot_discovery_SARS_CoV-2


Contact form

Get in touch directly with the above supplier

Your email address will not be communicated to any third party other than the above supplier for the purpose of fulfilling this enquiry. For more information: read our privacy policy.

Other products from this supplier